Strategy Training for Individuals With Unilateral Neglect
Launched by UNIVERSITY OF PITTSBURGH · May 1, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new training program designed to help people who have had a stroke and experience a condition called unilateral neglect. This condition makes it hard for individuals to pay attention to one side of their body or their surroundings, which can make daily activities challenging. The goal of the study is to see if a type of training called metacognitive strategy training can improve awareness and reduce difficulties caused by neglect.
To participate in this trial, individuals must be at least 18 years old, have had a stroke, and be currently receiving care in a rehabilitation facility. They also need to show signs of neglect based on specific tests. Unfortunately, those with severe language difficulties, dementia, or certain mental health conditions are not eligible. Participants can expect to engage in activities that aim to enhance their awareness and help them manage their daily tasks better. The study is currently recruiting, so there are opportunities for eligible individuals to join and potentially benefit from this innovative approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • primary diagnosis of stroke
- • admission to inpatient rehabilitation facility
- • ≥18 years old
- • presence of neglect as determined by score of \<18 on the Virtual Reality Lateralized Attention Test (VRLAT) or score below established cutoff for neglect on one of the six subtests of the Behavioral Inattention Test (BIT)
- Exclusion Criteria:
- • Boston Diagnostic Aphasia Examination (BDAE) Severity Scale score of 0 (severe global aphasia)
- • diagnosis of dementia indicated in medical record
- • diagnosis of active major depressive disorder/bipolar/psychotic disorder indicated in medical record
- • anticipated length of stay \<10 days
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Emily Grattan, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported